Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of Intravenous Delivery of Lomecel-B (Formerly Allogenic Longeveron Human Mesenchymal Stem Cells (LMSCs)) on VaccinE-Specific Antibody Responses in Subjects With Aging Frailty

NCT02982915 is registered in ClinicalTrials.gov with Longeveron Inc. as lead sponsor.

NCT NCT02982915
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02982915 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of Intravenous Delivery of Lomecel-B (Formerly Allogenic Longeveron Human Mesenchymal Stem Cells (LMSCs)) on VaccinE-Specific Antibody Responses in Subjects With Aging Frailty
Lead sponsor
Longeveron Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
November 30, 2016
Completion date
September 30, 2022
Enrollment
62 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

aging frailty